Could a common drug stop stomach cancer before it starts?
NCT ID NCT06590454
First seen Jan 05, 2026 · Last updated May 16, 2026 · Updated 24 times
Summary
This study tests whether the drug pyrvinium can reverse early changes in the stomach lining that may lead to cancer. About 32 adults with a high-risk precancerous condition called gastric intestinal metaplasia will receive either the drug or a placebo. The goal is to see if the drug reduces the number of precancerous spots and to learn more about the condition using lab-grown stomach tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC INTESTINAL METAPLASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Duke Health
RECRUITINGDurham, North Carolina, 27710, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.